Evidence map›Paper›PMID 20927401›Full record

Trial reportPloS one2010

Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling.

Sonemany Salinthone, Vijayshree Yadav, Robynn V Schillace, Dennis N Bourdette, Daniel W Carr

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Role of lipoic acid in multiple sclerosis.CNS neuroscience & therapeutics · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Role of Lipoic Acid in Testosterone Production in Males.The world journal of men's health · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sonemany SalinthonePortland Veterans Affairs Medical Center, Portland, Oregon, United States of America.
Vijayshree Yadav
Robynn V Schillace
Dennis N Bourdette
Daniel W Carr
Oregon Health & Science University · USPortland VA Medical Center · US

Funding

OREGON CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024140 · NCRR · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2006 to 2011
$61.1M
Lipoic acid as an immune modulator in multiple sclerosisK23AT003258 · NCCIH · OREGON HEALTH & SCIENCE UNIVERSITY · PI YADAV, VIJAYSHREE · 2005 to 2009
$670k
NCCIH NIH HHS K23 AT003258NCI NIH HHS CA1055ANCRR NIH HHS UL1 RR024140NCRR NIH HHS UL1RR024140
6 · The paper itself

Abstract

backgroundAbnormal regulation of the inflammatory response is an important component of diseases such as diabetes, Alzheimer's disease and multiple sclerosis (MS). Lipoic acid (LA) has been shown to have antioxidant and anti-inflammatory properties and is being pursued as a therapy for these diseases. We first reported that LA stimulates cAMP production via activation of G-protein coupled receptors and adenylyl cyclases. LA also suppressed NK cell activation and cytotoxicity. In this study we present evidence supporting the hypothesis that the anti-inflammatory properties of LA are mediated by the cAMP/PKA signaling cascade. Additionally, we show that LA oral administration elevates cAMP levels in MS subjects. METHODOLOGY/PRINCIPAL

findingsWe determined the effects of LA on IL-6, IL-17 and IL-10 secretion using ELISAs. Treatment with 50 µg/ml and 100 µg/ml LA significantly reduced IL-6 levels by 19 and 34%, respectively, in T cell enriched PBMCs. IL-17 levels were also reduced by 35 and 50%, respectively. Though not significant, LA appeared to have a biphasic effect on IL-10 production. Thymidine incorporation studies showed LA inhibited T cell proliferation by 90%. T-cell activation was reduced by 50% as measured by IL-2 secretion. Western blot analysis showed that LA treatment increased phosphorylation of Lck, a downstream effector of protein kinase A. Pretreatment with a peptide inhibitor of PKA, PKI, blocked LA inhibition of IL-2 and IFN gamma production, indicating that PKA mediates these responses. Oral administration of 1200 mg LA to MS subjects resulted in increased cAMP levels in PBMCs four hours after ingestion. Average cAMP levels in 20 subjects were 43% higher than baseline. CONCLUSIONS/SIGNIFICANCE: Oral administration of LA in vivo resulted in significant increases in cAMP concentration. The anti-inflammatory effects of LA are mediated in part by the cAMP/PKA signaling cascade. These novel findings enhance our understanding of the mechanisms of action of LA.

Indexed as

AdolescentAdultAgedCyclic AMPCyclic AMP-Dependent Protein KinasesHumansInterleukin-17Interleukin-6Leukocytes, MononuclearLymphocyte ActivationLymphocyte Specific Protein Tyrosine Kinase p56(lck)MaleMiddle AgedMultiple SclerosisSignal TransductionThioctic AcidCyclic AMPCyclic AMP-Dependent Protein KinasesInterleukin-17Interleukin-6Lymphocyte Specific Protein Tyrosine Kinase p56(lck)Thioctic Acid

Identifiers

PMID20927401
PMCPMC2946928
OpenAlexW2081055734

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.